{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-079608","form_type":"8-K","ticker":null,"cik":"0001618921","company_name":"Walgreens Boots Alliance, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.834060+00:00","generated_at":"2026-06-04T06:11:11.584960+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"WBA Q2 loss per share $6.85 on $5.8B VillageMD impairment; adj EPS $1.20, sales up 6.3%, guidance narrowed to $3.20-3.35","bullets":["GAAP loss per share $6.85 vs EPS $0.81 YoY; includes $5.8B after-tax non-cash VillageMD goodwill impairment.","Adjusted EPS $1.20, up 3.4% (2.8% constant currency), on sales $37.1B (+6.3% YoY).","Fiscal 2024 adjusted EPS guidance narrowed to $3.20-3.35 from prior range; U.S. Healthcare achieved adjusted EBITDA profitability.","Actions: cost savings target $1B, strategic portfolio review over next 3 months, early wind-down of sale-leaseback program.","Cencora share sales and challenging retail environment cited as headwinds; lower adjusted effective tax rate provides offset."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-079608","json":"https://secwatch.observer/filing/0001193125-24-079608.json","markdown":"https://secwatch.observer/filing/0001193125-24-079608.md","text":"https://secwatch.observer/filing/0001193125-24-079608.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618921/000119312524079608/0001193125-24-079608-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618921/000119312524079608/d817592d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:11:11.584960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"149b6765b3de7f4ea5f8e85cb84a436b111c5ecd","claim":"Walgreens Boots Alliance, Inc. reported the fiscal quarter ended February 29, 2024 results: revenue $37.1 billion, EPS $6.85. Guidance reaffirmed.","evidence_excerpt":"basis reflecting lower adjusted effective tax rate** and improved profitability in U.S. Healthcare • Second quarter sales increased 6.3 percent year-over-year to $37.1 billion, up 5.7 percent on a constant currency basis Fiscal 2024 guidance 1 • Narrowing fiscal 2024 adjusted EPS** guidance to $3.20 to $3.35, reflecting challenging retail environment","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618921/000119312524079608/0001193125-24-079608-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended February 29, 2024"},{"label":"Revenue","value":"$37.1 billion"},{"label":"EPS","value":"$6.85"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}